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Oxygen metabolism is essential for sustaining aerobic life, and normal cellular homeostasis works on a ﬁne balance between the
formation and elimination of reactive oxygen species (ROS). Oxidative stress, a cytopathic consequence of excessive production
of ROS and the suppression of ROS removal by antioxidant defense system, is implicated in the development of many diseases,
including Alzheimer’s disease, and diabetes and its complications. Retinopathy, a debilitating microvascular complication of di-
abetes, is the leading cause of acquired blindness in developed countries. Many diabetes-induced metabolic abnormalities are
implicated in its development, and appear to be inﬂuenced by elevated oxidative stress; however the exact mechanism of its devel-
opment remains elusive. Increased superoxide concentration is considered as a causal link between elevated glucose and the other
metabolic abnormalities important in the pathogenesis of diabetic complications. Animal studies have shown that antioxidants
have beneﬁcial eﬀects on the development of retinopathy, but the results from very limited clinical trials are somewhat ambiguous.
Although antioxidants are being used for other chronic diseases, controlled clinical trials are warranted to investigate potential
beneﬁcial eﬀects of antioxidants in the development of retinopathy in diabetic patients.
Copyright © 2007 R. A. Kowluru and P.-S. Chan. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Diabetes, a life long progressive disease, is the result of body’s
inability to produce insulin or use insulin to its full potential,
and is characterized by high circulating glucose. This disease
has reached epidemic proportion and has become one of the
most challenging health problems of the 21st century. It af-
fectsmorethan230millionpeopleworldwide,andthisnum-
ber is expected to reach 350 million by 2025. It is the fourth
leading cause of death by disease globally; every 10 seconds a
persondiesfromdiabetes-relatedcauses.IntheUnitedStates
an estimated 20.8 million people have diabetes, 14.6 million
of those have been diagnosed, but 6.2 million have not yet
been diagnosed. Unfortunately, the disease does not go away,
but it can be controlled. A study conducted by the Centers
for Disease Control suggests that diabetes care has improved
over the past 10 years; but there remains a great need to fo-
cus on additional improvements because about 850000 new
cases of diabetes are diagnosed each year in United States
alone.
Diabetes is a chronic disease and sustained hyperglyce-
mia attacks both microvessels and macrovessels throughout
the body. It is the leading cause of blindness and visual
impairment, noninjury amputation, and end-stage kidney
disease in adults in developed countries. It can threaten
vision; patients with diabetes develop cataracts at an earlier
age, and are nearly twice as likely to get glaucoma compared
to nondiabetics [1]. It is the primary cause of wound healing
impairments, and people with diabetes are two to four times
more likely to develop cardiovascular disease than people
without diabetes.
2. DEVELOPMENT OF DIABETIC RETINOPATHY
Diabetic retinopathy, a disease of the retina, is the leading
causeofacquiredblindnessinworkingadults.Themicrovas-
culature of the retina is damaged, the blood vessels swell and
leakﬂuid,andifnot prevented,newvesselsstarttogrow,and
ultimately lead to the detachment of the retina [2, 3]. It is a
duration-dependent disease that develops in stages; the inci-
dence of retinopathy is rarely detected in the ﬁrst few years of
diabetes, but the incidence increases to 50% by 10 years, and
to 90% by 25 years of diabetes. The prevalence of diabetic
retinopathy is increasing due to prolonged survival of dia-
betic patients. The National Eye Institute data is very alarm-
ing; it suggests that about half of the people with diabetes
in the United States have at least some form of retinopathy,
andabout700000havesomeseriousretinaldisease.Diabetic
retinopathy is aﬀecting approximately 65000 people in the2 Experimental Diabetes Research
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Figure 1: Glucose damages the retina via repeated acute and/or
cumulative changes. Continued high circulating glucose in dia-
betes can damage retina via many acute and cumulative long-term
changes that can cause tissue injury. Some acute insult, when re-
peated multiple times in this life-long disease, can result in cumula-
tive changes in stable macromolecules.
United States alone causing 12000 to 24000 new cases of
blindness each year.
Continued high circulating glucose in this life-long dis-
ease can damage retina via many acute (and repeated) and
alsocumulativelong-termchanges(Figure 1).Thecapillaries
of retina are lined with endothelial cells that are responsible
for maintaining the blood retinal barrier, and are supported
with an equal number of pericytes that help provide tone to
the vessels.However, indiabetes, theratio ofendothelial cells
t op e r i c y t e si sa l t e r e dt o4:1[ 4]. The blood vessels of retina
have tight junctions that protect them from leaking, but sus-
tained high glucose damages the tight junctions and the ves-
sels become leaky allowing ﬂuid or blood to seep into the
retina, thus resulting in the swelling of the retina [5]. Due to
progressive dysfunction, the capillaries die prematurely lead-
ing to ischemia that can be followed by neovascularization,
and ultimately retinal detachment and blindness [6, 7].
Inthedevelopmentofdiabetic retinopathy, thebasement
membrane thickens, the blood ﬂow is altered, and pericytes
and endothelial cells undergo accelerated apoptosis result-
ing in pericyte ghosts and acellular capillaries [8–12]. The
leukocytes become less deformable, and retinal leukostasis is
increased aﬀecting endothelial function [13]. Although the
biochemical abnormalities in the retina that are postulated
to be involved in the pathogenesis of retinopathy can be seen
within 2 months after induction of diabetes in rats, capil-
lary cell apoptosis and activation of caspase-3 are observed
after 6–8 months of diabetes [10, 11, 14–20]. Histopathol-
ogy of diabetic retinopathy takes over decades in humans
and about a year in rats to develop, and the small number
of apoptotic capillary cells in diabetic retina in diabetes [10–
12,20]couldhavemajorimpactontheformationofacellular
capillaries and pericyte ghosts. However, these abnormalities
do not present any clinical signs; the earliest clinical signs
are the appearance of microaneurysms. As the disease pro-
gresses, the endothelial cells try to repair the damaged vessel
by multiplying on the inner side of the vessel wall blocking
the capillaries. This ultimately results in ischemia and new
vessel growth. New capillaries start to grow from the surface
of the retinal veins towards the center of the eye with no sup-
port,andultimatelyresultinginthedetachmentoftheretina.
This suggests that the clinically silent initial phase of diabetic
retinopathy consists of irreversible cellular events with late
structural consequences.
In spite of extensive research, diabetic retinopathy has re-
mained diﬃcult to prevent and treat. Retinal photocoagula-
tion, the procedure introduced over half a century ago, re-
mains the best treatment for patients with diabetic retinopa-
thy to help prevent loss of vision, but it is often not eﬀec-
tive in restoring lost visual acuity. Photocoagulation is de-
structive, and can result in major adverse side eﬀects, includ-
ing loss of peripheral vision and color vision and decrease
in night vision [21]. Patients with vitreous hemorrhages can
undergo vitrectomy, but vitrectomy being a major surgery
carriesitsrisks.Thus,themaintenanceofgoodglycemiccon-
trolremainsasoneofthemosteﬀectiveoptionstopreventor
delay the worsening of diabetic retinopathy. Good glycemic
control can help lower the risk for developing retinopathy
by 76%, and lower the risk for progression by 54% in type
1 diabetic patients. Reduction of glycated hemoglobin by
only 1 unit (8% to 7%) can reduce the risk of retinopathy
(and other diabetic complications) by over 30%. However,
good glycemic control, for most of the patients, is diﬃcult
to achieve and to maintain for a long duration. This requires
modiﬁcation of behavior, dedication by the patient and the
loved ones, increased risk of hypoglycemic seizure and possi-
ble weight gain [22], thus leaving the patient striving for the
best possible, sensible glycemic control. An understanding of
themechanismofdiabeticretinopathyisimportantforeluci-
dating its pathogenesis to identify potential future therapies
for treating this sight threatening disease.
2.1. Oxidativestressindiabetes
Undernormalphysiologicalconditions,approximately0.1%–
5% of oxygen that enters the electron transport chain is
reduced to superoxide; a reactive oxygen species (ROS) and
the rest are used in metabolic processes. ROS can also be
generated from other sources other than the mitochondrial
electron transport chain including, cytochrome P450, the
NAD(P)H oxidase(s), and nitric oxide synthases [23].
ROS are produced continuously in all cells to support
normal cellular functions. However, excess production of
ROS originating from endogenous or exogenous sources,
or ineﬃcient removal of ROS, could result in patholog-
ical conditions. ROS produced during normal oxidative
metabolism are eliminated by an eﬃcient scavenging system,
but an imbalance between production and scavenging
of ROS can result in excessive levels of either molecular
oxygen or ROS, thus resulting in increased “oxidative stress.”
Hence, oxidative stress is the cytopathic consequence of
the generation of excess ROS beyond the capacity of a
cell to defend against them, and represents an imbalance
between excess formation and/or impaired removal of ROS.
Consequences of chronic oxidative stress include damage to
biological macromolecules such as DNA, lipids, proteins,R. A. Kowluru and P.-S. Chan 3
and carbohydrates, disruption in cellular homeostasis, and
generation of other ROS creating further damage resulting
in many disease processes of clinical interest [24].
Diabetesresultsinincreasedoxidativestress,andelevated
oxidativestressplaysanimportantroleinthepathogenesisof
diabetic complications [25]. Increased oxidative stress in di-
abetes is postulated to promote the development of neuropa-
thy [26], nephropathy [27, 28], myocardial injury [29], and
retinopathy [30]. The possible sources of oxidative stress in
diabetes might include autooxidation of glucose, shifts in re-
dox balances, decreased tissue concentrations of low molec-
ular weight antioxidants such as reduced glutathione (GSH)
and vitamin E, and impaired activities of antioxidant de-
fenseenzymessuchassuperoxidedismutase(SOD)andcata-
lase [16, 31–33]. ROS generated by high glucose are consid-
ered as a causal link between elevated glucose and the other
metabolicabnormalitiesimportantinthedevelopmentofdi-
abetic complications [34]. However, the exact mechanism by
which oxidative stress could contribute to the development
of diabetic complications still remains to be clariﬁed.
2.2. Oxidativestressanddiabeticretinopathy
The retina has high content of polyunsaturated fatty acids
and has the highest oxygen uptake and glucose oxidation rel-
ative to any other tissue. This phenomenon renders retina
more susceptible to oxidative stress [35]. It has been sug-
gested that the correlation between hyperglycemia, changes
in the redox homeostasis, and oxidative stress are the key
events in the pathogenesis of diabetic retinopathy. Animal
studies have demonstrated that oxidative stress contributes
not only to the development of diabetic retinopathy but also
totheresistanceofretinopathy toreverseaftergoodglycemic
controlisreinstituted—themetabolicmemoryphenomenon
[30]. Resistance of diabetic retinopathy to reverse is probably
attributed to accumulation of damaged molecules and ROS
that are not easily removed even after good glycemic control
is reestablished.
Superoxide levels are elevated in the retina of diabetic
rats and in retinal cells incubated in high glucose media
[36–38], and hydrogen peroxide content is increased in the
retina of diabetic rats [39]. Membrane lipid peroxidation
and oxidative damage to DNA (indicated by 8-hydroxy-
2-deoxyguanosine, 8-OHdG), the consequences of ROS-
induced injury, are elevated in the retina in diabetes [16, 17,
36, 40].
Since oxidative stress represents an imbalance between
excess formation and/or impaired removal of ROS, the an-
tioxidant defense system of the cell is a crucial part of the
overall oxidative stress experienced by a cell. In diabetes,
the activities of antioxidant defense enzymes responsible for
scavenging free radicals and maintaining redox homeosta-
sis such as SOD, glutathione reductase, glutathione perox-
idase, and catalase are diminished in the retina [16, 33].
Further, the cell is equipped with intracellular antioxidant,
GSH; GSH is probably the most important defense the cell
is equipped with. It can act as an ROS scavenger and modu-
late intracellular redox state [41]. The levels of this intracel-
lular antioxidant are decreased in the retina in diabetes [42],
and the enzymes responsible for its metabolism are com-
promised [43, 44]. Apart from the antioxidant defense en-
zymes, nonenzymic antioxidants such as vitamin C, vitamin
E, and β-carotene that exist biologically for the regulation of
redox homeostasis are also depressed during hyperglycemia-
induced oxidative stress [45].
2.3. Oxidativestressanddysmetabolismindiabetes
Oxidative stress, besides creating a vicious cycle of damage to
macromolecules by amplifying the production of more ROS,
also activates other metabolic pathways that are detrimental
to the development of diabetic retinopathy (Figure 2). These
include the polyol pathway [46], the advanced glycation end
product (AGE) pathway [47], protein kinase C (PKC) path-
way [48, 49], the hexosamine biosynthesis pathway [50], al-
teration in the expressions of vascular endothelial growth
factor (VEGF) [51] and insulin-like growth factor-1 (IGF-1)
[52], and elevation in mitochondrial overproduction of su-
peroxide and mitochondrial dysfunctions [53]. Several of
these pathways may also mediate oxidative stress creating
an interrelated connection with oxidative stress as well as
with other pathways that amplify tissue damage even fur-
ther. However, it has been diﬃcult to pinpoint which path-
way/s is/are critical to the development of diabetic retinopa-
thy. More likely, no one metabolic dysfunction is the sole
contributor and possibly all pathways interact to create the
histopathology changes seen in diabetic retinopathy.
One of the hyperglycemia-induced metabolic perturba-
tions in diabetic retinopathy is the polyol pathway. The pol-
yol pathway involves the conversion of glucose into sorbitol,
and the reaction is catalyzed by aldose reductase. Sorbitol
is then oxidized to form fructose by sorbitol dehydroge-
nase. Increased polyol pathway in diabetes could enhance
oxidative stress because aldose reductase requires NADPH,
and increased polyol pathway activity is postulated to de-
plete NADPH by competing with glutathione reductase for
NADPH. This could reduce the availability of NADPH for
regenerating the intracellular antioxidant, GSH [54].
Another pathway of cellular metabolism that mediates
the toxic eﬀects of glucose is the production of AGEs. The
AGEs are produced from strong glycating dicarbonyl com-
pounds such as methylglyoxal and glyoxal [55]. Chronic
hyperglycemia favors glycation reactions and nonenzymatic
glycation that can lead to the alterations in function, ac-
tivity, and degradation of both intracellular and extracellu-
lar proteins via chemical rearrangement and cross-linking.
The AGEs formed on amino groups of proteins, lipids, and
DNA can cause intramolecular and intermolecular cross-
links. In diabetes, the accumulation of AGE and its receptor,
RAGE, is increased in the retinal microvasculature [56]. In
the late stages of retinopathy, AGEs are irreversibly formed
and they accumulate within retinal capillary cells. It is postu-
latedthatmoreROSaregeneratedviatheAGEpathwaylead-
ing to the activation of nuclear transcriptional factor, NF-kB,
and causing further damage to the cells [57]. The AGEs in-
crease nitrative stress in the retinal vascular cells and initiate4 Experimental Diabetes Research
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Figure 2: Oxidative stress-mediated dysmetabolisms in diabetic retinopathy. Oxidative stress is a cytopathic consequence of excessive pro-
ductionofreactiveoxygen species (ROS)andthesuppressionofROSremoval byantioxidantdefensesystem.Hyperglycemia-induced oxida-
tive stress is considered a causal link between elevated glucose and other metabolic abnormalities important in the development of diabetic
complications. Several diabetes-induced abnormalities in the retina that are postulated in the development of retinopathy are inﬂuenced by
oxidative stress, and are considered to be interrelated.
a sequence of events leading to retinal capillary cell apop-
tosis via activation of NF-kBa n dc a s p a s e - 3[ 58]. Nitration
of proteins can inactivate mitochondrial and cytosolic pro-
teins; disrupt protein assembly and functions, and increase
apoptosis, ultimately leading to pathological consequences
and damage of cellular constituents [59].
The activation of PKC is also considered as a major path-
way implicated in the pathogenesis of diabetic retinopathy
[49, 60, 61]. High glucose levels increase the release of ROS
and the synthesis of diacylglycerol (DAG) increasing the ac-
tivity of PKC [48, 62]. Activated PKC can bring about a vari-
ety of changes characteristic of diabetic retinopathy that in-
clude increasing vessel permeability, blood ﬂow, alteration of
hormone and growth factor receptor recycling, stimulation
of neovascularization, endothelial proliferation and apopto-
sis, and regulating the action of several factors such as VEGF,
IGF-1, and transforming growth factor β [63–65]. Inhibition
of PKC activation by PKCβ speciﬁc inhibitor (LY53331) is
shown to prevent diabetes-induced oxidative stress [17, 66].
Further, recent studies by Dr. Kings’s group have shown that
lack of PKCβ isoform in mice protects them from diabetes-
induced oxidative stress [67]. These data suggest that oxida-
tive stress and PKC are indeed interrelated, and support the
role of PKC in ROS-mediated diabetic complications.
The hexosamine biosynthesis pathway is yet another
pathway that may mediate some of the toxic eﬀects of high
glucose and superoxide concentrations in the cell [50]. The
inhibition of glyceraldehyde 3 phosphate dehydrogenase
(GAPDH), a multifunctional protein with diverse cytoplas-
mic membrane and nuclear activities, by ROS causes the
diversion of all glycolytic metabolites to the hexosamine
pathway producing UDP-N-acetylglucosamine which is a
substrate used for the post-translational modiﬁcation of
intracellular factors including transcription factors [68]. In-
hibitionofGAPDHcanresultinincreasedlevelsofglycolytic
metabolite glyceraldehyde 3 phosphate that can activate the
AGE pathway by activating intracellular AGE precursor
methylglyoxal [47, 69]. In addition, GAPDH can also be
modiﬁed by direct glycation and by nitration [70, 71], and
overexpression of manganese SOD (MnSOD) decreases the
activation of GAPDH. Our recent results have shown that
GAPDH activity is decreased in the retina obtained from
diabetic rats compared to the age-matched normal control
rats (Kowluru et al., unpublished observations), suggestingR. A. Kowluru and P.-S. Chan 5
that GAPDH-related mechanism could be playing an im-
portant role in the pathogenesis of diabetic retinopathy.
VEGF, an angiogenesis inducer, plays a pivotal role in
diabetic retinopathy and is implicated as the mediator and
initiator of nonproliferative and proliferative diabetic reti-
nopathies, respectively, [72, 73]. Oxidative stress mediates
the hyperglycemia-induced pathological eﬀects of VEGF
on microvascular complications of diabetes [51]. Retinal
expression of VEGF is elevated by ROS [74], and VEGF can
also interact with other metabolic pathways important to
the development of retinopathy such as PKC and the polyol
pathway [75, 76].
IGF-1 can have direct mitogenic eﬀects on endothelial
cells including increased proliferation, chemotaxis, and an-
giogenesis, and it can stimulate glucose transport into retinal
microvascularendothelialcellsviaactivationofPKC;andcan
modulate the expression and activity of VEGF [52]. Similar
to VEGF, the activation of IGF-1 also increases DAG levels
and PKC activation [77]. Although the exact role of IGF-1 in
the pathogenesis of diabetic retinopathy remains to be eluci-
dated, it is possible that IGF-1 can be modulated by oxidative
stress via PKC pathway.
There is increasing evidence to indicate ROS as media-
tors of pathological signal transduction pathways. ROS can
serve as important downstream eﬀectors for both Ras and
Rac proteins [78]. Oxidative stress-induced Ras activation is
reported to participate in the development of retinopathy in
diabetes [18]. Oxidative stress can also activate a redox sensi-
tive NF-kB, and NF-kB is also a key regulator of antioxidant
enzymes [19]. Thus, activation of NF-kB is another plausible
avenue via which oxidative stress can modulate the develop-
ment of retinopathy in diabetes.
2.4. Oxidativestressandmitochondrialdysfunctions
During hyperglycemia glucose oxidation is increased pro-
ducing an elevation in voltage gradient across the mitochon-
drial membrane. When a critical threshold in voltage gra-
dient is reached, electron transfer inside complex III of the
electron transport chain is blocked. The electrons accumu-
late at coenzyme Q that then donates them to molecular
oxygen creating a lot of superoxide [79]. Mitochondria are
the principal endogenous source of superoxide. Mitochon-
drial superoxide production initiates a cascade of damag-
ing events via the production of more superoxide, hydro-
gen peroxide, hydroxyl radicals, and peroxynitrite which in-
jure macromolecules either at or near the site of their for-
mation [80]. Chronic overproduction of ROS in the retina
results in aberrant mitochondrial functions in diabetes [53].
Hyperglycemia-induced overproduction of superoxide by
the mitochondrial electron transport chain is considered to
activate the major pathways of hyperglycemic damage by in-
hibiting GAPDH activity, and glucose-induced increase in
superoxide induces mutations in mitochondrial DNA result-
ing in defective subunits of the electron transport complexes
eventually causing increased superoxide production at phys-
iological concentrations of glucose [34, 69]. The activity of
complexIIIisreducedintheretinalmitochondriaofdiabetic
mice and diabetic rats, and the levels of nitrotyrosine are ele-
vated in the retinal mitochondria of diabetic mice compared
to nondiabetic mice [81, unpublished observations].
OneoftheROS-induceddysfunctionsinmitochondriais
the repression of antioxidant defense capabilities that could
lead to enhanced sensitivity of retinal cells to oxidative stress
because they cannot scavenge ROS eﬀectively. The isoform
of SOD in the mitochondria, MnSOD, together with GSH,
is suppressed in the diabetic and high glucose-cultured reti-
nal mitochondria [81–83]. Mitochondrial dysfunction also
includesdamagetomitochondrialDNA[84],andmitochon-
drial DNA damage is increased in the retina in diabetes [81].
Damage to the mitochondrial lipid membrane by ROS in-
creases the permeability of the organelle, and the modula-
tion of the permeability transition of mitochondrial mem-
brane represents another dysfunction caused by ROS. In-
creasedswellingofthemitochondriaisobservedintheretina
of diabetic mice [81]. The inner mitochondrial membrane
spacecontainsseveralsolubleproteinsincluding cytochrome
c;thereleaseofcytochromecfrommitochondriatothecyto-
plasm and Bax translocation from the cytosol to mitochon-
dria that could drive cell apoptosis are increased in the retina
and its capillary cells in diabetes [36].
Thus, it is evident that oxidative stress can modulate mi-
tochondria function resulting in increased apoptosis of reti-
nal capillary cells; however, additional studies to determine
the role of oxidative stress-induced mitochondrial dysfunc-
tions in diabetic retinopathy are warranted.
2.5. Oxidativestressandapoptosis
It is widely known that apoptosis of retinal cells is a con-
summatedphenomenonindiabeticretinopathy.Retinalcap-
illary cells undergo accelerated apoptosis that precedes the
detection of any histopathology changes characteristic of
this diabetes complication [10, 11]. Exposure of the peri-
cytes and endothelial cells to high glucose or diabetic ani-
mals showed an increase in oxidative stress, caspase-3 activ-
ity, and other transcription factors leading to capillary cell
death [16, 19, 20, 85]. Terminal transferase dUTP nick end
labeling (TUNEL) positive cells are observed in rat and mice
retinal microvasculature at 6 to 8 months of diabetes [10–
12, 86]. The histological evidence of apoptosis is also sup-
portedbysomeofthebiochemicalobservationsthatdemon-
strated an increase in the expression of Bax in the diabetic
retina[87].Theseﬁndingssubstantiatethatapoptosisofreti-
nal capillary cells is mediated through sequential events.
Retinal Muller cells, ganglion cells, astrocytes, and pho-
toreceptors are also aﬀected early on in the course of the
development of diabetic retinopathy [88–90], and their role
in the pathogenesis of diabetic retinopathy is being investi-
gated by several other laboratories. Although the exact sig-
naling steps to retinal capillary cells apoptosis in diabetic
retinopathy remain unclear, the results have pointed to the
involvement of oxidative stress-activated caspases and NF-
kB in retinal cell death [19, 20], and inhibition of superoxide
accumulation in diabetes prevents apoptosis of retinal cap-
illary cells [36, 82, 83]. The mechanism by which oxidative6 Experimental Diabetes Research
stress can increase apoptosis appears to be complex, but
could involve increases in membrane lipid peroxidation and
oxidative injury to the macromolecules essential for cellu-
lar functions, and alterations in signal transduction and gene
expression [91, 92]. ROS can indirectly induce apoptosis by
changingcellularredoxpotentials,depletingGSHandreduc-
ing ATP levels [93]. In retinal pericytes obtained from dia-
betic patients, the altered gene proﬁle of scavenging enzymes
correlates with the overexpression of the cell death protease
gene, suggesting an important role of oxidative stress in per-
icyte dropout seen in diabetic retinopathy [94]. The release
of ROS increases mitochondrial pore permeability that in
turn triggers the release of cytochrome c and other proapop-
totic factors from retinal mitochondria initiating apoptosis
via activation of caspases [95, 96], and increased cytochrome
c is observed in the retina and its capillary cells in diabetes
[36, 53, 83].
Caspases, a group of cysteine proteases that are essential
for mediating apoptosis in cells [97], are known to be
very sensitive toward oxidative and nitrative stress [98].
ROS-induced mitochondrial dysfunction pertaining to the
release of cytochrome c can result in activation of caspase-9
which initiates a cascade of events that activates caspase-3
responsible for fragmenting DNA [96, 99]. Caspase-3 is
activated in the retina in diabetes, and the therapy that
inhibits the development of retinopathy in diabetic rats also
inhibits retinal caspase-3 activation [20], suggesting that
increased oxidative stress can modulate retinal cell apoptosis
in diabetes via caspase-3 pathway.
Another apoptosis execution mediator is the redox
sensitive-NF-kB. Although the eﬀects of NF-kBa c t i v a t i o n
canbeeitheranti-orproapoptoticdependingonthecelltype
and disease state, diabetes-induced activation of NF-kBi n
the retina and its capillary cells is considered to be proapop-
totic [19, 87]. The activation of NF-kB is considered a key
signaling pathway by which high glucose induces apoptosis
in endothelial cells [100]. Diabetes-induced NF-kBa c t i v a -
tion is reported to trigger a proapoptotic program in reti-
nal pericytes [101]. We have shown that NF-kBi sa c t i v a t e d
in endothelial cells and pericytes incubated in high glucose
medium, and in retina in diabetes before either cell death
or histopathology can be seen, and this continues during the
time when the histopathology is developing, suggesting that
the activation of NF-kB is an early event in the development
of diabetic retinopathy [19]. Activation of NF-kBm o d u l a t e s
the expression of several proinﬂammatory factors, including
tumor necrosis factor and inducible nitric oxide synthase,
and this, in turn, can result in increased free radical pro-
duction [102]. Reaction between superoxide and nitric oxide
(NO) forms peroxynitrite, which can increase DNA damage,
induce formation of 8-OHdG, and deplete intracellular GSH
levels. Peroxynitrite is a powerful oxidant that can react with
awiderangeoftargetstocauseoxidationofmembranephos-
pholipids, protein and nonprotein thiols, results in single-
strand DNA breaks, and nitrates tyrosine residues [103]. It
caninjuremitochondrialeadingtoincreaseinmitochondrial
pore opening and consequently apoptosis [104, 105]. Perox-
ynitrite levels are elevated in retina early in diabetes and re-
main elevated at 14 months of diabetes in rats [19, 106], and
increased nitrotyrosine can be localized in the retinal vascu-
lature of diabetic rats [107].
2.6. Oxidativestressandinﬂammation
Diabetic retinopathy shares similarities with chronic inﬂam-
matory disease [108], and inﬂammation may play a cen-
tral role in the development and progression of diabetic
retinopathy. ROS is considered as a strong stimulus for the
release of cytokines [109], and increased superoxide can
promote inﬂammation through various pathways; they can
damage endothelial cells, increase microvascular permeabil-
ity and release cytokines, and help in the recruitment of neu-
trophils at the site of inﬂammation [110]. Thus, the role of
oxidative stress in the inﬂammation-mediated development
of diabetic retinopathy needs further investigation.
The activation of NF-kB by ROS could increase proin-
ﬂammatory mediators such as the cytokines, NO, and pros-
taglandins [111]. The levels of cytokines including inter-
leukin (IL)-1β, IL-6, and IL-8 are increased in the vitreous
ﬂuid of patients with proliferative diabetic retinopathy [112]
and in the retina of diabetic rats and mice [113, 114]. The
levels of IL-1β are increased substantially also in retinal
capillary cells incubated in high glucose media [114]. Stimu-
lation of IL-1 can lead to the release of more ROS and NF-kB
activation, and this could create a continuous feedback
loop [109, 115]. We have shown that IL-1β administration
into the vitreous of normal rats increases oxidative stress
in the retina and this increase is similar to that observed in
diabetes [114, 116]. The apoptosis of retinal capillary cells
also increases with IL-1β, and this is believed to be mediated
by the activation of NF-kBa n dc a s p a s e - 3[ 106, 114, 116].
Cyclooxygenase-2 (COX-2) that catalyzes the formation
of prostaglandin E2 (PGE2) is induced by IL-1, and COX-2
and PGE2 are reported to contribute to the development of
diabeticretinopathybymodulatingVEGF-mediatedvascular
permeability and angiogenesis [117]. Thus, oxidative stress
may directly or indirectly induce the release of inﬂammatory
mediators and the inﬂammation process implicated in the
pathogenesis of diabetic retinopathy.
3. TREATMENTS FOR DIABETIC RETINOPATHY
Since there remains a strong understanding that oxidative
stress may be the instigator of all other dysmetabolisms
implicated in the pathogenesis of diabetic retinopathy, the
use of appropriate antioxidants may have potential on the
metabolic and functional abnormalities in diabetic retinopa-
thy. Antioxidants may act at diﬀerent levels; they may inhibit
the formation of ROS or scavenge free radicals, or increase
the antioxidants defense enzyme capabilities.
Lipoic acid is an antioxidant capable of thiol-disulﬁde
exchange. It is able to scavenge ROS and reduce metabolites
such as glutathione to maintain a healthy cellular redox state
[118]. It distributes to the mitochondria and serves as a
critical cofactor for the mitochondrial enzyme complexes,
and is regenerated via glycolytic ﬂux. Lipoic acid attenuatesR. A. Kowluru and P.-S. Chan 7
the apoptosis of rat retinal capillary cells and decreases
the levels of 8-OHdG and nitrotyrosine [12]. Lipoic acid
supplementation completely prevents diabetes-induced
increase in nitrotyrosine and activation of NF-kB while
decreasing the levels of VEGF and oxidatively modiﬁed pro-
teins in the rat retina [12, 119]. This antioxidant also inhibits
diabetes-induced decreases in retinal mitochondrial and
cytosolic ratios of NAD+ to NADH [120]. We have shown
that long-term administration of lipoic acid prevents the
development of diabetic retinopathy in rats, the number of
apoptotic capillary cells and acellular capillaries is decreased
in the retina of diabetic rats [12].
Benfotiamine, a lipid soluble thiamine (vitamin B1) de-
rivative that inhibits MnSOD, has been shown to inhibit in-
creases in acellular capillaries in the retina of diabetic rats
via blocking the major pathways involved in hyperglycemia-
induced retinal dysmetabolism, including AGEs, PKC, and
hexosamine pathways [121].
Green tea, rich in polyphenols with great antioxidant
potency, inhibits lipid peroxidation, and scavenges hydroxyl
and superoxide radicals [122]. Green tea supplementation in
diabetic rats is reported to improve the levels of SOD and
GSH,reducetheserumglucoselevels,andimproveretinopa-
thy as evident by reductions in acellular capillaries and per-
icyte ghosts [123]. This provides encouraging rationale for
its possible therapeutic use to inhibit retinopathy in diabetic
patients.
Trolox is a water soluble analog of vitamin E with potent
antioxidant properties. Trolox is shown to partially prevent
the loss of pericytes in diabetic rats via reducing membrane
lipid peroxidation [124]. However, no additional followup
studies have been reported by either the same group or other
investigators.
Nicanartine, an antioxidant with cholesterol lowering
properties, can partially inhibit pericyte loss in diabetic rats.
However, in the same animals it fails to provide any beneﬁt
in normalizing diabetes-induced increase in retinal acellular
capillaries [125].
Zinc, a trace element with antioxidant properties, is
shown to prevent diabetes-induced glutathione loss in the
retina [126]. Further, another trace element, selenium, is re-
ported to down-regulate VEGF production in the retina in
diabetes [127].
Dietary supplementation with multiantioxidants com-
prising of vitamins C and E in diabetic rats prevents inhibi-
tion in retinal glutathione reductase, glutathione peroxidase,
and SOD activities [44]. Superoxide production in the retina
is repressed by the same combination of vitamins in diabetic
rats [123]. Partial reductions in the development of retinal
acellular capillaries and pericyte ghosts are seen in diabetic
rats given the combination of vitamins C and E [16]. In an-
other study, the same combination of antioxidants is shown
to decrease pericyte dropout signiﬁcantly in the retina of di-
abetic rats [123]. The beneﬁts pertaining to retinal cells sur-
vival are more profound in diabetic rats consuming multi-
antioxidants containing more components including ascor-
bic acid, α-tocopherol acetate, Trolox, N-acetyl cysteine, β-
carotene, and selenium. Besides decreasing microvascular le-
sions, the multiantioxidants abrogate the diabetes-induced
increases in retinal PKC and NO [16]. The same components
of multiantioxidants other than decreasing retinal PKC ac-
tivity also reduce lipid peroxide, and prevent the decrease
in SOD, glutathione reductase, and catalase activities [128].
Thus, by increasing the diversity of antioxidants, retinopathy
isbetterpreventedintheanimalmodelsofdiabeticretinopa-
thy.
Our recent studies using genetic manipulation tech-
niques have shown that overexpression of mitochondrial
SOD in mice can prevent diabetes-induced decrease in
retinal oxidative stress, and protect the mitochondria from
dysfunction [83], this raises the possibility that MnSOD
mimics could provide an attractive pharmacological ap-
proach to inhibit the development of diabetic retinopathy.
Thus, there is accumulating evidence from animal stud-
ies that oxidative stress is associated with the development
of retinopathy in diabetes, and antioxidants have beneﬁcial
eﬀects on the development of retinopathy. However, the re-
sults from clinical trials are ambiguous. Calcium dobesilate
(2,5-dihydroxybenzenesulfonate), a compound with potent
antioxidant capacity against hydroxyl radical, and a regis-
tered compound for the treatment of diabetic retinopathy,
is shown to reduce the progression of this sight-threatening
complication of diabetes [129]. Pycnogenol, a compound
with both free radical scavenging and antiinﬂammatory
properties, is also reported to have beneﬁcial eﬀects on the
progression of retinopathy in diabetic patients [130]. Vita-
min E treatment in clinical trials has been shown to inhibit
diabetes-induced retinal hemodynamics [131].
In contrast, others have found no signiﬁcant associa-
tions between serum levels of major dietary antioxidants and
retinopathyintype2diabeticpatients[132,133]andasingle
24-hour diet recall study has provided no beneﬁcial eﬀects of
supplementation with vitamins C, E, and β-carotene [134].
The diﬀerences for such discrepancies are not clear, but it
is possible that the initiation of antioxidants could be sub-
sequent to the development of background retinopathy, in
contrast to the animal studies where antioxidants have been
administered soon after establishment of diabetes, and addi-
tional trials need to be initiated. Or, this could be that the
antioxidant concentrations in the retina were not suﬃcient
to produce beneﬁcial eﬀects. These over the counter antioxi-
dants appear to be promising in inhibiting the development
of diabetic retinopathy in animal models. But further clini-
cal studies are needed to determine the appropriate regimen,
and also whether these therapies could have long-term ef-
fects that may help diabetic patients to slow the progression
of this sight-threatening complication of diabetes. The clin-
icians need to caution the patients so that the patients are
made aware of possible shortcomings before initiating such
therapies.
We need to recognize that since diabetes-induced met-
abolicabnormalitiesareinterrelatedinretina[17],inhibiting
a single detrimental pathway of retinal metabolism in dia-
betes might have multiple beneﬁcial eﬀects on retinopathy.
But, if the treatment does not completely inhibit the targeted
metabolic abnormality, this could result in partial inhibition8 Experimental Diabetes Research
of other interrelated abnormalities. Thus, we might not have
one single drug that could eﬀectively treat this complication
of diabetes, and it may be prudent to use a group of drugs
with divergent mode(s) of action to combat this multifacto-
rial complication, and antioxidants could be an integral part
of that regimen.
DEFINITIONS
AGE: Advanced glycation end product
AR: Aldose reductase
COX-2: Cyclooxygenase-2
DAG: Diacylglycerol
GAPDH: Glyceraldehyde 3 phosphate dehydrogenase
GSSG: Oxidized glutathione
GSH: Reduced glutathione
IGF-1: Insulin-like growth factor-1
IL: Interleukin
MnSOD: Manganese superoxide dismutase
NF-kB: Nuclear transcription factor
NO: Nitric oxide
8-OHdG: 8-hydroxy-2’-deoxyguanosine
PGE2: Prostaglandin E2
PKC: Protein kinase C
ROS: Reactive oxygen species
SDH: Sorbitol dehydrogenase
SOD: Superoxide dismutase
TGF-β: Transforming growth factor-β
VEGF: Vascular endothelial growth factor
TUNEL: Terminal transferase dUTP nick end labeling
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